[1] |
YU Yong, MA Shouliang, SHENG Yuqin.
Allergic Reactions and Treatment Involving Sodium Dimercaptopropane Sulfate Injection during Copper Chelation for Wilson’s Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 771-775.
|
[2] |
GUO Dongqi, WANG Hao, BAI Xin, BAI Jianqi, SU Hongmei, ZHANG Jingru, GUO Xiaofei, ZHAO Xiaoqi, WANG Min, WANG Yuan, ZHANG Ping.
Identification of Druggable Targets for Intervertebral Disc Degeneration Based on Multi-Omics Data-Driven Mendelian Randomization and Prediction of Traditional Chinese Medicine Interventions
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 241-248.
|
[3] |
NIE Xiaolu, ZHAO Houyu, HUO Donghui, YAN Aixia, SUN Feng, PENG Xiaoxia, NI Xin, ZHAN Siyan.
Pediatric Drug-Induced Immune Thrombocytopenia Based on Real World Data and Quantitative Structure-Activity Relationship
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 16-22.
|
[4] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[5] |
DING Xiaoli, HU Xinyue, WANG Xuelei, SUN Yue, LI Jing, ZHANG Hui, Liang Chenggang, WANG Yan.
Quality evaluation of insulin glargine injections
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 644-650.
|
[6] |
SHI Guanhong, WANG Qi, SUN Hao, CHEN Yanjie, CHU Ziyan, JIANG Ao, TANG Zaixiang, LIU Jingfang.
Safety signal analysis of antidepressants use in fetus and neonate based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 687-692.
|
[7] |
WANG Chunnan, QIN Shiru, ZHANG Meng, SONG Haibo, LIU Junchang, LI Ge, SUN Feng.
Evaluation of drug safety with multicenter real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 703-708.
|
[8] |
CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Management of compound glycyrrhiza oral solution and recommendations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
|
[9] |
SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui.
Adverse events of abemaciclib in breast cancer patients based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.
|
[10] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[11] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
[12] |
SONG Fuyu, CAO Yi.
Establishment of Key Performance Indicators for Drug Inspection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1411-1414.
|
[13] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[14] |
DU Ying, XIE Yanming, WANG Lianxin, GENG Hongjiao, LI Xiangjie.
Clinical characteristics and drug combination analysis of Lianhua Qingwen capsules (granules) in the real world
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 296-300.
|
[15] |
WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei.
Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
|